References
- World-Health-Organisation. Cardiovascular Diseases (cvds) World-Health-Organisation; Geneva, Switzerland: 2013.
- Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99: 2239–42.1022608710.1161/01.CIR.99.17.2239
- Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40(3): 209–94.1289231710.1080/713609354
- Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013; 226(2): 305–14.2308368110.1016/j.atherosclerosis.2012.09.012
- Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81(5): 761–7.1739272510.1038/sj.clpt.6100167
- Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition bysaxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol 2012; 12: 2.2247504910.1186/1471-2210-12-2
- Jianqiang Z, Qiuyue C, Jixin Z, Chaohong L, Bing Z, Quan G. DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs. Front Immunol 2019; 10: 1050.10.3389/fimmu.2019.0105031134095
- Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223: 133.2130421710.1620/tjem.223.133
- Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2016; 8: 26.10.1186/s13098-016-0144-627006706
- Chen K, Zhuo T, Wang J, Mei Q. Saxagliptin upregulates nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus. Metab Syndr Relat Disord 2018; 16: 336–41.10.1089/met.2018.001029912623
- Hussain M, Atif MA, Ghafoor MB. Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients. Pak J Pharm Sci 2016; 29: 2385–9.28167482
- Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011; 29: 520–8.2115064010.1097/HJH.0b013e328341939d
- Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012; 60: 833–41.10.1161/HYPERTENSIONAHA.112.19511522868389
- Sufiun A, Rafiq K, Fujisawa Y, Rahman A, Mori H, Nakano D, et al. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertens Res 2015; 38: 237–43.2558885010.1038/hr.2014.173
- Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol 2012; 60: 467–73.10.1097/FJC.0b013e31826be20422932707
- Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36: 119–30.10.1159/000341487
- Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsuprykov O, Reichetzeder C, et al. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens 2013; 31: 2290–8.10.1097/HJH.0b013e3283649b4d24077249
- Pari L, Chandramohan R. Modulatory effects of naringin on hepatic key enzymes of carbohydrate metabolism in high-fat diet/low-dose streptozotocin-induced diabetes in rats. Gen Physiol Biophys 2017; 36(3): 343–52.2863561110.4149/gpb_2016055
- Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, Di-Petrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008; 21(12):1288–91.10.1038/ajh.2008.30118846043
- Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension 2015; 65: 238–49.10.1161/HYPERTENSIONAHA.114.0463125368027
- Lago RM, Singh PP, Nesto RW. Diabetes and hypertension. Nat Clin Pract Endocrinol Metab 2007; 3(10): 667.10.1038/ncpendmet063817893686
- Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223(2): 133–5.2130421710.1620/tjem.223.133
- Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K et al. The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes. J Korean Med Sci 2012; 27(11): 1364–70.10.3346/jkms.2012.27.11.136423166419
- Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48(5): 592–8.1835399610.1177/0091270008316885
- Gouni-Berthold I, Hanssen R, Ravarani L, Berthold HK. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. Curr Pharm Des 2017; 23(31): 4573–82.28911306
- Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56: 728–33.10.1161/HYPERTENSIONAHA.110.15655420679179
- Monami M, Vitale V, Ambrosio VL, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 2012; 29(9): 736–46.2292316110.1007/s12325-012-0045-5
- Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 173–7.10.1016/j.regpep.2004.08.02415582729
- Shah Z, Pineda C, Kampfrath T, Maiseyu A, Ying Z, Racoma I, et al. Acute DPP-4 inhibition modulates vacular tone through GLP-1 independent pathways. Vascular Pharmacol 2011; 55(1–3): 111–7.
- da Silva Júnior WS, Souza M, Nogueira Neto JF, Bouskela E, Kraemer-Aguiar LG. Constitutive DPP4 activity, inflammation, and microvascular reactivity in subjects with excess body weight and without diabetes. Microvasc Res 2018; 120: 94–9.3007120310.1016/j.mvr.2018.07.005
- Schon E, Demuth HU, Eichmann E, Horst HJ, Korner IJ, Kopp J, et al. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol 1989; 29: 127–32.
- Avogaro A, Giorda C, Maggini M, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007; 30: 1241–7.10.2337/dc06-255817290034
- Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–91.10.1056/NEJMoa070624518256393
- Derosa G, Tritto I, Romano D, D'Angelo A, Catena G, Maffioli P. Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. J Clin Pharmacol 2019 doi: 10.1002/jcph.1431. [Epub ahead of print].31131461
- Addison, D, and Aguilar, D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atheroscler Rep 2011; 13(2): 115–22.2117061110.1007/s11883-010-0153-0
- Saad, M.I., Kamel, M.A., and Hanafi, M.Y. Modulation of adipocytokines production and serum NEFA level by metformin, glimepiride, and sitagliptin in HFD/STZ diabetic rats. Biochem Res Int 2015: 138134.25838947
- Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018; 38(1): 56–63.2942749210.1111/liv.13676
- Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 1981; 68: 1106–7.10.1172/JCI1103357287903
- Kim SJ, Nian C, McIntosh CH. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem 2007; 282: 8557–67.10.1074/jbc.M60908820017244606
- Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49: 452–8.10.1007/s00125-005-0126-y16447057
- Masuda D, Kobayashi T, Sairyou M, Hanada H, Ohama T, Koseki M, et al. Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial). J Atheroscler Thromb 2018; 25(6): 512–20.10.5551/jat.4134329199201